Description

Like 2022, 2023 is expected to exhibit the fundamental trends affecting the manufacturing industries in the post-COVID era, where the availability of device components and skilled labor remain scarce.

In 2023, the medical device industry is faced with growing challenges, from the unpredictability of the demand to components and product shortages and bottle necks to sterilization and logistics. In this environment, contract development and manufacturing organizations carry a growing responsibility to fulfil the needs of medical care operators.

Join us for this webinar to learn about the current trends shaping the US medical device outsourcing landscape, with a particular focus on its performance and business outlook, and sustained M&A activity.

Download “The 2023 U.S. MedTech Contract Manufacturing Report” to learn more about the latest industry trends and their meaning for medical device CDMOs and their capital sponsors, providing insight into the market trends with a critical view of the opportunities and risks that lie ahead.

Register Now! 

SPEAKER

Carlo Stimamiglio Carlo Stimamiglio has over 15 years of experience in deal making roles and a global track record of healthcare transactions. After early experiences in asset management and corporate finance roles, Carlo joined Alira Health in 2014 and he has developed multiple practices in the Transaction Advisory Division. Carlo is a recognized research author and opinion leader in the global pharmaceutical and medical device CDMO markets, fields in which he regularly advises M&A transactions. Carlo leads Alira Health’s global MedTech investment banking practice, supporting companies in the structuring and execution of financing, M&A and global licensing deals. Carlo’s role includes leadership of Alira Health’s Corporate M&A activities at Alira Health and has led more than 10 corporate acquisitions since 2018. Carlo holds a MS in Finance from the University of Verona and an MBA from IE Business School. He is a licensed investment banking representative, holding FINRA Series 79 and 63 licenses.